Experimental drug shows promise for kaposi sarcoma lesions
NCT ID NCT07539454
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called nirogacestat in 28 people with Kaposi sarcoma skin tumors. The drug blocks a protein that helps tumors grow, aiming to shrink lesions and stop them from spreading. While not a cure, it may offer a new way to control the disease in people who haven't responded to other treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AIDS-RELATED KAPOSI SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Siteman Cancer Center at Washington University
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug shows promise in blocking kaposi sarcoma growth
- Small study tracks daily life impact of kaposi sarcoma treatment
- Could an old HIV drug beat kaposi sarcoma?
- Could a cancer drug tame kaposi sarcoma in HIV patients?
- HIV cancer study reveals who gets sick and why
- New hope for HIV patients: cheaper chemo may work just as well for kaposi sarcoma